Payment overview · 2025
General Payments
$55,830.42
114 reported records · 9 companies
Healthcare provider profile · identity verified
Rohit Mehta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · FLORENCE, SC · NPI 1598989196
Verified facts
What the public records show
CMS Open Payments records show Rohit Mehta, MD received $55,830.42 in general payments during 2025 across 114 reported records.
Philips North America LLC accounted for 40.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Philips North America LLC | Unresolved — no canonical attribution shown | $22,424.00 | 40.2% | 45 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18,663.39 | 33.4% | 26 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $10,133.40 | 18.1% | 13 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $4,050.96 | 7.3% | 13 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $196.56 | 0.3% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $145.14 | 0.3% | 8 | 2025 |
| Flowphysix Inc | Unresolved — no canonical attribution shown | $106.30 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $61.73 | 0.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $48.94 | 0.1% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $28,744.26 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,800.00 | 6 |
| Travel and Lodging | $6,513.46 | 31 |
| Food and Beverage | $3,772.70 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $12,506.34 | 18 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $10,133.40 | 13 | 2025 |
Source payment records
|
|||||
| IGT Devices Systems Undivided Normalized: igt devices systems undivided |
Device | Philips North America LLC | $6,171.81 | 3 | 2025 |
Source payment records
|
|||||
| LM Undivided Normalized: lm undivided |
Device | Philips North America LLC | $3,477.17 | 19 | 2025 |
Source payment records
|
|||||
| EVERA MRI XT DR SURESCAN Normalized: evera mri xt dr surescan |
Device | Medtronic, Inc. | $1,069.59 | 8 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $196.56 | 1 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $145.14 | 8 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $114.31 | 1 | 2025 |
Source payment records
|
|||||
| Fleet Management Normalized: fleet management |
Device | Philips North America LLC | $113.25 | 2 | 2025 |
Source payment records
|
|||||
| FLOWRUNNER Normalized: flowrunner |
Device | Flowphysix Inc | $106.30 | 1 | 2025 |
Source payment records
|
|||||
| Mechanical Tools Normalized: mechanical tools |
Device | Philips North America LLC | $98.31 | 1 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $96.54 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $95.27 | 2 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $82.49 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOSIGHT READER Normalized: cardiosight reader |
Device | Medtronic, Inc. | $73.33 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $61.73 | 4 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $42.19 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $36.15 | 1 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $34.32 | 3 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $30.75 | 2 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Spotcheck Services Normalized: spotcheck services |
Device | Philips North America LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 340 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 32 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 25 |
| Flecainide Acetate | Flecainide Acetate | 54 | 27 |
| Furosemide | Furosemide | 49 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 42 | 20 |
| Xarelto | Rivaroxaban | 39 | 15 |
| Losartan Potassium | Losartan Potassium | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 12 |
| Sucralfate | Sucralfate | 28 | 28 |
| Carvedilol | Carvedilol | 27 | 11 |
| Atorvastatin Calcium | Atorvastatin Calcium | 20 | suppressed |
| Omeprazole | Omeprazole | 20 | 20 |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Lisinopril | Lisinopril | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55,830.42 · 114 records | Philips North America LLC | AFFERA MAPPING SYSTEM, AMVIA EDGE, AURORA EV-ICD MRI SURESCAN, AVEIR, Acticor 7 VR-T DX, BIOMONITOR, CARDIOSIGHT READER, CARTO 3, COBALT DR MRI SURESCAN, Coronary Undivided, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, EVERA MRI XT DR SURESCAN, FLOWRUNNER, Fleet Management, IGT Devices Systems Undivided, IGT Devices Undivided, LM Undivided, LifeVest, MICRA, Mechanical Tools, PERCLOSE PROSTYLE, Rhythmia Mapping System, Spotcheck Services | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error